Early vessel destabilization mediated by Angiopoietin-2 and subsequent vessel maturation via Angiopoietin-1 induce functional neovasculature after ischemia. by Qin, Di et al.
Early Vessel Destabilization Mediated by Angiopoietin-2
and Subsequent Vessel Maturation via Angiopoietin-1
Induce Functional Neovasculature after Ischemia
Di Qin1,2, Teresa Trenkwalder1,3, Seungmin Lee1, Omary Chillo3, Elisabeth Deindl3, Christian Kupatt1,4,
Rabea Hinkel1,4*
1Medizinische Klinik und Poliklinik I, Klinikum Großhadern, Munich, Germany, 2Department of Senile Disease, China-Japan Union Hospital of Jilin University, Changchun,
Jilin, People’s Republic of China, 3Walter-Brendel-Centre of Experimental Medicine, LMU Munich, Munich, Germany, 4DZHK (German Centre for Cardiovascular Research),
partner site Munich Heart Alliance, Munich, Germany
Abstract
Background: We assessed whether Angiopoietin-2 (Ang2), a Tie2 ligand and partial antagonist of Angiopoietin-1 (Ang1), is
required for early vessel destabilization during postischemic angiogenesis, when combined with vascular growth factors.
Methods: In vitro, matrigel co-cultures assessed endothelial-cell tube formation and pericyte recruitment after stimulation
of VEGF-A, Apelin (APLN), Ang1 with or without Ang2. In a murine hindlimb ischemia model, adeno-associated virus (rAAV,
361012 virusparticles) transduction of VEGF-A, APLN and Ang1 with or without Ang2 (continuous or early expression d0-3)
was performed intramuscularly (d-14). Femoral artery ligation was performed at d0, followed by laser doppler perfusion
meassurements (LDI) 7 and 14. At d7 (early timepoint) and d14 (late timepoint), histological analysis of capillary/muscle fiber
ratio (CMF-R, PECAM-1) and pericyte/capillary ratio (PC-R, NG2) was performed.
Results: In vitro, VEGF-A, APLN and Ang1 induced ring formation, but only APLN and Ang1 recruited pericytes. Ang2 did not
affect tube formation by APLN, but reduced pericyte recruitment after APLN or Ang1 overexpression. In vivo, rAAV.VEGF-A
did not alter LDI-perfusion at d14, consistent with an impaired PC-R despite a rise in CMF-R. rAAV.APLN improved perfusion
at d14, with or without continuous Ang2, increasing CMF-R and PC-R. rAAV.Ang1 improved perfusion at d14, when
combined with rAAV.Ang2 (d0-3), accompanied by an increased CMF-R and PC-R.
Conclusion: The combination of early vessel destabilization (Ang2 d0-3) and continuous Ang1 overexpression improves
hindlimb perfusion, pointing to the importance of early vessel destabilization and subsequent vessel maturation for
enhanced therapeutic neovascularization.
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Introduction
Molecular evidence demonstrates the feasibility of vessel growth
in ischemic muscle tissue (for review cf. [1,2]). If applied to patients
suffering from manifest atherosclerosis of the heart or peripheral
vessels, this fundamental principle would add to the therapeutic
armamentarium of ischemic muscle disease. The surgical or
interventional treatment options, though highly efficient and
constantly improved, may at times be exhausted leaving a growing
number of no option patients without functional revascularization.
Earlier trials with neovascularization therapy yielded inconsis-
tent results [3] which indicated a necessity to further improve
therapeutic agents or combinations thereof in order to translate
the biological principle of balanced vascular growth into
treatment. Currently, three distinct processes of neovascularization
appear as minimal requirements for efficient vascular therapy:
capillary growth (angiogenesis) and pericyte recruitment (matura-
tion), followed by conductance vessel growth (arteriogenesis) [2].
In the recent years, microvessel maturation advanced to become
an important target of therapeutic neovascularization, the lack of
which would impair the efficient perfusion of microvessels and the
successful growth of conductance vessels [4–6].
Physiologically, several processes mark the development of
stable neovessels: first, degradation of extracellular matrix (ECM)
and opening of pre-existing capillaries; second sprouting of
endothelial cells forming a new tube consisting of tip cells at the
top of stalk cells, third extension of endothelial tube guided into
avascular area by gradients of angiogenic growth factors such as
VEGF-A, fourth the assembly of new vascular basement
membrane (BM) and finally recruitment of mural cells (pericytes
and smooth muscle cells) to the neo-endothelial cells. Mature
microvessels are required to efficiently perform blood perfusion
providing nutrition and oxygen to the ischemic tissue. In contrast,
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immature capillaries lacking the investment of mural cell are prone
to capillary regression and fading of an initial angiogenic response
[7].
The Angiopoietin/Tie2 system regulates vascular maturation
during development and postnatal angiogenesis. Ang1 binding to
the Tie2 receptor has emerged as an essential event in the
maintenance of a quiescent vasculature [8]. Ang1 acts by
strengthening the contact between endothelial cells as well as
endothelial cells and pericytes [9] and by increasing the migration
of mural cells towards endothelial cells [10,11]. Of note, Ang1 is
also capable of induction of endothelial cell proliferation and
migration [12,13], and modulates VEGF-A induced neovascular-
ization in vivo [14,15]. Angiopoietin-2, in contrast, competes with
Ang1 binding at the level of its receptor Tie2 inducing
destabilization and regression of microvessels [16]. Ang2 trans-
genic mice reveal an impaired neovascularization after hindlimb
ischemia induction [17].
For therapeutic neovascularization, a delicate balance appears
desirable: whereas early destabilization may support the initial
capillary proliferation process, subsequent maturation is required
for the development of functional and lasting microvascular
networks. In accordance, resistance to early destabilization may
inhibit the sprouting of neovascularization and reduce the
angiogenic response. Therefore, controlled early destabilization
followed by enforced maturation of neo-vessels may constitute an
attractive and novel concept of therapeutic angiogenesis in vivo. In
the present study, we tested this hypothesis by evaluating Ang2 in
combination therapies of three distinct profiles: In a first series, we
assessed the combination of Ang2 and VEGF-A, a growth factor
efficiently inducing capillary proliferation, but weakly providing
capillary maturation [6,7]. Second, we tested the combination of
Ang2 and APLN, a growth factor providing both, capillary
proliferation and maturation, leading to stable and non-leaky
vessels [18]. Third, we assessed the potential of early Ang2-
induced destabilization (d0-3) on top of continuous Ang1-
overexpression providing neovessel maturation.
Materials and Methods
Animals
Animal care and all experimental procedures were performed in
strict accordance to the German and NIH animal legislation
guidelines and were approved by the Bavarian Animal Care and
Use Committee (AZ 55.2-1-54-2531-130-8 and 35-12). All animal
experiments were conducted at the Walter Brendel Centre of
Experimental Medicine.
Plasmids and virus
For cell transient transfection we used plasmid cDNA contain-
ing target gene (pcDNA, hVEGF-A, mAPLN, mAng2 and hAng1)
controlled by the constitutive viral promoter cytomegalovirus
(CMV). The tet-off gene expression system was utilized for mAng2
conditional turn-off by doxycycline (Dox) in the late stage. It
contains two critical components: one is regulatory protein TetR
and VP16. The latter converts the former to the hybrid protein
tetracycline-controlled transactivator (tTA). Another is the re-
sponse plasmid expressing the target gene with the minimal CMV
promoter (PminCMV), and a tetracycline response element (TRE)
upstream of the tTA which activates transcription in the absence
of Dox. Production of recombinant adeno-associated viral vector
was performed using a triple transfection method as described
earlier [19]. In brief, plasmid one serves as a helper plasmid,
plasmid two encodes for the AAV rep and cap sequences and the
third plasmid encodes for the transgen including the CMV
promoter. rAAV production is performed via U293 cell transfec-
tion and caesium gradient purification of the vectors [20]. Titer of
the rAAVs was determined using rt-PCR utilizing the polyA tail of
the vector bGH (primers: 5’-tctagttgccagccatctgttgt-3 forward, 5’-
tgggagtggcaccttcca-3’ reverse). Trans and helper plasmids were
kindly provided by James M. Wilson, University of Pennsylvania.
rAAV vectors were produced for the transgenes: CMV-LacZ,
CMV-hVEGF-A, CMV-mAPLN, CMV-mAng2, CMV-tetoff-
mAng2 and CMV-hAng1.
Quantitative real-time PCR analysis
Successful transfections were confirmed by quantitative real-
time PCR analysis (BIO-RAD, MyiQ, single color Real-Time
PCR Detection System, Cat.No. 170-9740). The AAV vectors
were applied to ischemic limb 14 days before artery ligation via
i.m. injection. Muscle tissue of the lower limb (left and right
gastrogenmius muscle) was obtained at day 7 after femoral artery
ligation. qRT-PCR was performed as followed: Total RNA was
extracted by using the Trizol Reagent-RNA/DNA/Protein
Isolation Reagent (Molecular Research Center, Cat.No. TR-118)
and transcribed into cDNA using IQ SYBR,RGREEN Supermix
(BIO-RAD, Cat.No. 170-8882). Primers for detection of overex-
pression were: VEGF-A forward (59- TTT TAC GCT ATG TGG
ATA CGC-39) and reverse (59-AAG AGA CAG CAA CCA GGA
TTT-39); Ang2 forward (59-TCG AAT ACG ATG ACT CGG
TG -39) and reverse (59-GTT TGT CCC TAT TTC TAT C -39);
APLN forward (59-GGC CAT CAC CAG CCA TTC CTT G-39)
and reverse (59-GCA GCG TTA GCA GCA GCA TAG-39);
Ang1 forward (59- GGT GGT TTG ATG CTT GTG G -39) and
reverse (59- GGA TTC TAG TTG TGG TTT GTG-39); S18
forward (59-GACCCATTCGAACGTCGTCCCTATCAA-39)
and reverse (59-GTAATTTGCGCGCTTGCTGCCTTCCTT-
39). The baseline and threshold were adjusted according to the
manufacturer’s instructions. The relative abundance of transcripts
was normalized using the expression level of S18 mRNA. The data
of the treated ischemic leg were compared to the sham operated
leg and to non-treated control animals (Fig. S1).
In vitro tube formation assay and co-culture
Human microvascular endothelial cells (HMECs) or murine
endothelial cells (bEnd.3) were cultured in Dulbecco’s modified
Eagle’s medium (DMEM +10% fetal calf serum (FCS) and 1% P/
S); Pericytes (C3H/10T1/2, ATCC) were cultured in the
complete growth medium including Eagle’s Basal medium
(BME) with 2 mM L-glutamine, 1.5 g/L sodium bicarbonate,
Earle’s BSS and 10% FCS. Expression of pericyte specific markers
were analyzed via FACS measurements. After washing the
pericytes in PBS, cells were incubated with primary antibody
against NG-2 (Millipore AB 5320) and PDFG-R (abcam ab91066
rat monoclonal) for 45 min. Incubation with secondary antibody
(for NG2 Molecular Probes anti-rabbit Alexa 488 A11008, for
PDGF-R anti-rat sekunda¨r: anti-rat-PE Santa Cruz sc-3740) was
performed after washing of the cells for 45 min. Isotype controls
were only incubated with the secondary antibody (Fig. S2A,B).
Tube formation of HMECs and co-culture of HMECs or
bEnd.3 cells with pericytes in 2D matrigel assay was performed to
analyse the interaction of pericytes and endothelial cells in vitro.
ECs were transfected with pCMV-VEGF-A, pCMV-Ang2, and/
or pCMV-APLN, pCMV-Ang1 in 24-well plate for 48 h. The co-
transfection with two plasmids did not alter the expression level
achieved via single pcDNA transduction. (Fig. S2) The ECs
(HMECS and bEnd.3) were diluted to a final concentration of
16104 cells/50 ml in endothelial cell growth medium (ECGM)-
containing 5% FCS and 1% P/S, stained with DiD (red, Vybrant,
Role of Vessel Maturation in Neovascularization
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Cat.No. 22887). Cells were plated on matrigel in angiogenesis m-
slides (ibidi, Cat.No. 81501). After 18 h tube formation was
investigated and pictures were taken for quantification. The green
stained pericytes (DiO, Vybrant, Cat.No. 22886) where added to
the tubes in a concentration of 16103 cells/20 ml. After 6 h
fluorescence pictures for red (endothelial cells) and green
(pericytes) were taken and the pericyte per ring ratio was
calculated.
Mouse hindlimb ischemia model
In male C57BL/6J mice (n = 7 per group, Charles River,
Sulzfeld, Germany) i.m. injection into the whole limb (10
injections 5 ml each) was performed with rAAV.hVEGF-A (high
dose was 361012 virus particles, low dose was 561011 virus
particles), rAAV.mAPLN, rAAV.hAng1, with or without co-
application of rAAV.Ang2 or rAAV.tetoff-mAng2 (361012 virus
particles), 14 days before surgery. Hindlimb ischemia model was
performed as described previously. [21,22] In brief, the right
femoral artery was ligated distally of the profunda fermoral artery,
whereas the ligature at the sham operated left femoral artery was
only loosely winded around the artery at the same position.
Laser Doppler imaging
Hind-limb perfusion was assessed using laser doppler perfusion
imaging (MoorLDI-2; Moor Instruments, Devon, UK) [22]. After
general anesthesia of the mice with 1.5% Isoflurane, mice were put
in a heating chamber and maintained at 37uC. After an adaption
time of 10 min in the heating chamber, measurements were
conducted. LDI measurements were carried out before and after
surgery on day 0 d, 7 d and 14 d. Results are given as right to left
leg ratio including subtraction of background tissue value.
Immunofluorescent histochemical staining
Tissue from the gastrocnemius muscle was harvested at day 7
(early timepoint) and day 14 (late timepoint) after femoral artery
ligation. Tissue was embedded in tissuetech, stored at 280uC, cut
to 5 mm slices and endothelial cells were stained with a CD31 goat
anti-mouse polyclonal IgG (Santa Cruz, Cat.No. sc1506, dilution
1:200) for primary antibody. A donkey anti-goat IgG-R (Santa
Cruz, Cat.No. sc2094, dilution 1:200) was used as secondary
antibody. Pericyte staining was performed via NG2 staining
(primary antibody of Chondroitin Sulfate Proteoglycan, Millipore,
Cat.No. AB5320, dilution 1:200) and secondary antibody of
bovine anti-rabbit IgG FITC (Santa Cruz, Cat.No. sc2365,
dilution 1:200). Capillary density was analyzed as the ratio of
CD31 positive cells per muscle fiber (CMF-R), and the maturation
of capillaries was represented by pericyte to capillary ratio (PC-R).
From each mouse 5 random pictures from the gastrocnemius
muscle were analyzed.
Statistical analysis
All data are presented as mean 6 SEM and analyzed by SPSS
19.0 software. Comparisons among groups were made by one-way
ANOVA testing with Gabriel’s post hoc test. Games-Howell
analysis was used for heterogeneity of variance. Differences
between groups were considered significant for p-value of ,0.05.
Results
Angiopoietin-2 antagonizes pericyte recruitment to
growing tubes in vitro
First, we sought to establish an in vitro model of pericyte
recruitment to growing tubes. Therefore, DiD-labeled, growth-
factor-transfected endothelial cells (HMECS or bEnd.3) embedded
in matrigel were seeded with DiO-labeled pericytes. Tube analysis
revealed that VEGF-A, despite robust tube formation (4563
tubes/lpf vs. 1962 tubes/lpf in control), did not alter pericyte
recruitment (1.760.2 pericyte/tube vs. 1.860.2 pericytes/tube in
control, Fig. 1A,B, Fig. S3A). In contrast, APLN, known to
provide stable, non-leaky vessels in vivo [23], increased both,
capillary proliferation (4363 tubes/lpf, Fig. 1C) and pericyte
investment (3.060.1 perictes/tube, Fig. 1D, Fig S3B). Ang1 was
also capable of inducing tube formation and pericyte recruitment
(Fig. 1E,F, Fig. S3C). Ang2, however, which did not alter the
already limited pericyte attraction to VEGF-A treated endothelial
cells, lowered the number of pericytes attracted to both, the
APLN- (1.960.2 pericytes/tube) and the Ang1-transfected cell
group (1.960.1 pericytes/tube). In vitro, tube formation capacity
of APLN was unaffected by Ang2 (3663 tubes/lpf, Fig. 1C), but
suffered in the case of Ang1, when Ang2 was present (Fig 1E).
These in vitro experiments promped us to assess the effect of
Ang2 in combination with VEGF-A, APLN and Ang1 in vivo.
Early perfusion recovery of ischemic hindlimbs (d7) does
not improve upon rAAV.VEGF-A, but decreases after
combining VEGF-A+Angiopoietin-2
Employing a murine hindlimb ischemia model, we investigated
the impact of VEGF-A, a well-characterized pro-angiogenic agent
with weak vessel maturation potential. The overexpression of
target genes (pCMV-hVEGF-A, pCMV-mAng2, pCMV-tetoff-
mAng2, pCMV-mAPLN, pCMV-hAng1) as well as the reporter
gene (CMV-LacZ), which were applied intramuscular via recom-
binant AAV (rAAV) vectors, was analyzed by qRT-PCR and
histology (Fig. S1). Analysis of ischemic hindlimb perfusion by LDI
indicated that rAAV.VEGF-A-either low dose (561011 virus
particles, 0.6660.10 LDI ratio (r/l)) or high dose (361012 virus
particles, 0.4860.08 LDI ratio (r/l))-did not alter the recovery of
perfusion (0.6560.04 LDI ratio (r/l) in control, Fig. 2A,B),
whereas the combination of high rAAV.VEGF-A and rAAV.Ang2
significantly impaired perfusion recovery at d7 (0.3660.05 LDI
ratio (r/l)).
To explore the effect VEGF-A and Ang2 on angiogenesis
capillary sprouting in vivo, we analyzed capillary/muscle fiber
ratio (CMF-R, PECAM-1 staining) and pericyte/capillary ratio
(PC-R, NG2 staining) by fluorescence histology (Fig. 2C-E). Of
note, CMF-R was upregulated in the high rAAV.VEGF-A
(1.4060.03 CMF-R), but not in the low rAAV.VEGF-A
(1.3260.01 CMF-R) compared to control (1.2860.01 CMF-R).
In addition, the combination of high rAAV.VEGF-A with Ang2
revealed a significant higher CMF-R (1.4760.01 CMF-R, Fig. 2D)
than control group. In contrast, PC-R was decreased in the
rAAV.VEGF-A/Ang2 group (0.3160.02 PC-R) compared to
control (0.4760.02 PC-R) and low and high rAAV.VEGF-A
treatment groups (0.4260.01 PC-R for low and 0.3960.02 PC-R
for high VEGF-A, Fig 2E). Taken together, even though hVEGF
alone and in combination with Ang2 significantly induces capillary
growth, the failure to provide pericyte coverage is associated with a
lack of perfusion recovery of the ischemic hindlimb, compared to
controls and low VEGF. The combination of hVEGF and Ang2
even further decreased pericyte covarage and thereby showed a
trend to a lower perfusion than the hVEGF alone.
Late neovascularization (d14) is not provided by VEGF-A
combined with Angiopoietin-2
In the next step we asked whether an intensified vessel
destabilization allows for more capillary growth and a potential
Role of Vessel Maturation in Neovascularization
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Figure 1. Capillary growth and maturation profile of VEGF-A, APLN and Ang1 with or without Ang2 in vitro. (A) Capillary-like tube
formation was enhanced by VEGF-A alone transfection in HMECs (16104 per well of m-slide angiogenesis plate) on 2D-matrigel. (B) 16103 Pericytes
labeled by DiO (green) are plated after capillary-like tube formation of HMECs with DiD labeling (red). 24 h later, co-cultures reveal a low rate of
pericytes attraction by VEGF-A, which was unaffected by Ang2. (C) Apelin (APLN) promoted tube formation with or without Ang2. (D) Pericyte
recruitment was enhanced by Apelin, an effect attenuated by Ang2. (E) Ang1 induced tubes formationin the absence of Ang2. (F) However, the tube
maturation provided by Ang1 was abolished in the presence of Ang2. (MEAN 6 SEM, n = 5, ** p,0.01).
doi:10.1371/journal.pone.0061831.g001
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Figure 2. The failed therapeutic neovascularization after VEGF-A overexpression in the early stage (7 day) of mouse hindlimb
ischemia model. (A) Laser Doppler Imaging (LDI) measured after right femoral artery ligation and at d7. (B) Quantification of LDI (ischemic versus
non-ischemic hindlimb) revealed no significant neovascularization by VEGF-A at low (rAAV.lVEGF-A) or high doses (rAAV.hVEGF-A), but deterioration
of perfusion in the rAAV.hVEGF-A+Ang2 group compared vehicle group (#P,0.05, vs. vehicle). (C) Fluorescence microscopy images of
gastrocnemius muscle sections from control (rAAV.LacZ) or ischemic hind limb co-stained with DAPI (blue, nucleus), anti-NG2 (green, pericyte)
antibody and anti-PECAM-1 (red, endothelial cell) antibody at d 7 after ligation. (D) Quantitative evaluation of capillary/muscle fibre ratio (CMF-R)
demonstrated the ability of high VEGF-A with or without Ang2 to induce capillary growth in vivo. (E) Pericyte coverage was unaffected by lVEGF-A,
but reduced in hVEGF-Agroup compared to vehicle group and even further reduced through the co-application of rAAV.Ang2. (MEAN 6 SEM, n= 7,
* p,0.05, ** p,0.01).
doi:10.1371/journal.pone.0061831.g002
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late gain of perfusion (d14). As indicated in Fig. 3A,B, whereas no
significant gain of perfusion was achieved by rAAV.hVEGF-A
only, the combination of VEGF-A and continuous Ang2 delivery,
which impaired perfusion recovery at d7 (Fig. 2), did not impair
perfusion at d14 compared to controls (0.8860.03 LDI ratio (r/l)
in control vs 0.7760.14 LDI ratio (r/l) in hVEGF-A+Ang2).
Histologically, the higher CMF-R in the hVEGF-A+Ang2 group
(1.7460.04 CMF-R vs. 1.3160.02 CMF-R in controls, Fig. 3C,D)
was offset by a significantly decreased PC-R (0.4260.01),
compared to control (0.6960.02 PC-R) and VEGF-A muscle
specimen (0.6260.02 PC-R in hVEGF-A, Fig. 3C,E).
Early Apelin-induced neovascularization is antagonized
by permanent, but not temporary Angiopoietin-2
overexpression
Since VEGF-A did not provide a gain of perfusion in the
ischemic hindlimb, we investigated the potential of apelin (APLN),
a vascular growth factor inducing capillary sprouting and
maturation, to improve perfusion after ischemia induction.
Indeed, rAAV.APLN sufficed to significantly increase perfusion
at d7 (0.8960.06 LDI ratio (r/l), Fig. 4A, B). This effect was
completely abolished by co-application of rAAV.Ang2 (0.6860.05
LDI ratio (r/l)), in fact reducing the perfusion at d7 to control
level. Histological analysis revealed that the gain of CMF-R
induced by APLN (1.3460.01) was even increased by rAAV.Ang2
coapplication (1.5660.03) Fig. 4C,D). However, the PC-R, which
was significantly increased upon apelin stimulation (0.7260.01),
was reduced to control level after rAAV.APLN/Ang2 co-
application (0.5460.01 PC-R, Fig. 4E). Thus, the improved early
perfusion (d7) after APLN overexpression critically depended on
pericyte recruitment. Preventing pericyte recruitment by Ang2-
cotreatment sufficed to block a gain of perfusion upon apelin,
despite an even improved capillary growth.
Next, we investigated whether temporary Angiopoietin-2
expression would improve the efficacy of APLN. Since we found
that APLN induces vessel maturation in vitro, we compared both,
either continuous or early vessel destabilization by Ang2. The
latter was achieved by Doxycycline-inducible (Tet-off) Ang2,
which allowed to switch off Ang2 expression significantly (Fig
S1D). Using Doxycycline from d3 on, we limited Ang2 expression
to d0-3 and investigated whether early Ang2 overexpression may
boost APLN-induced vessel growth. Of note, we found a strong
trend towards improvement of perfusion (0.8060.04 LDI ratio (r/
l), p = 0.08) (Fig. 4A,B) in the rAAV.APLN+Ang2 (d0-3) group,
which co-incided with improved CMF-R (1.5960.02) compared
to rAAV.APLN only and improved PC-R (0.6760.01), compared
to rAAV.APLN+Ang2 (Fig. 4C–E). However, although early Ang2
overexpression favorably altered capillary growth and maturation
indices at d7, it did not suffice to improve early hindlimb perfusion
provided by APLN.
Late neovascularization is provided by Apelin with or
without Angiopoietin-2
In contrast, rAAV.APLN provided a significantly increased
perfusion at d14 (1.0460.02 vs. 0.8860.03 LDI ratio (r/l)), an
effect still present during continuous co-expression of APLN and
Ang2 (1.1060.12 LDI ratio (r/l)), but not after APLN + Ang2 (d0-
3) transduction, which provided Ang2 only in the first 3 days of
postischemic vessel growth (Fig. 5A,B). The capillary/muscle fiber
ratio increased in both, the rAAV.APLN and the rAAV.APL-
N+Ang2 groups and after rAAV.Apln+Ang2 (d0-3) transduction
(Fig. 5C,D). The pericyte/capillary ratio, which was provided by
APLN alone at d14, was significantly reduced in the APLN+Ang2-
treated animals (Fig. 5C,E), whereas temporary overexpression of
Ang2 showed a non-significant trend towards reduction of pericyte
coverage. Thus, although APLN+Ang2 was efficient in improving
capillarization at d14, a lack of mature vessels was associated with
a lack of further improvement of perfusion beyond the level
provided by APLN alone. When Ang2 overexpression is limited to
the d0-3 period and switched off by Doxycycline application
thereafter, Apelin fails to further increase perfusion above control
level, and did not provide capillary growth or pericyte investment
(Fig. 5A–E).
rAAV.Angiopoietin1 requires temporary Angiopoietin2
expression for functional early vessel growth
Next, we assessed the potential of Angiopoietin-1, an antagonist
of Ang2 and a powerful vessel maturation factor. Of note, neither
Ang1 nor Ang2 induced significant increase of perfusion alone
(0.7860.06 LDI ratio rAAV.Ang1 and 0.7260.06 LDI ration
rAAV.Ang2, Fig. 6A,B). However, a combination of Ang1 and
temporary overexpression of Ang2 (d0-3) (Fig. S1E) provided a
significant gain of perfusion (Fig. 6A,B) at d7, along with a high
capillary/muscle fiber ratio and a high pericyte/capillary ratio
(Fig. 6C–E). rAAV.Ang1 and rAAV.Ang2 alone did not improve
capillary growth (PECAM-1 positive cells, Fig. 6C,D), whereas
pericyte coverage of the capillaries was enhanced after Ang1
overexpression and unaltered after Ang2 application (Fig. 6C,E).
Late neovascularization is provided by Angiopoietin-1
combined with early Angiopoietin-2 treatment (d0-3)
Next, we assessed the late-timepoint efficacy of sequential Tie2-
activation by Ang2 (d0-3) and continuous rAAV.Ang1 overex-
pression. In contrast to rAAV.Ang1 or rAAV.Ang2 alone, which
failed to significantly exceed the control groups perfusion at d14
(Fig. 7A,B), we could demonstrate a profound sustained gain of
perfusion by combining Ang1 with early Ang2 overexpression
(Fig. 7A,B). This effect was accompanied by an improved
capillary/muscle fiber ratio (CMF-R) in the Ang1+Ang2 (d0-3)
group (1.6160.08 CMF-R, Fig. 7C,D) as well as an increase in
pericyte coverage (0.8060.03 PC-R, Fig. 7C,E). Neither rAA-
V.Ang1 nor rAAV.Ang2 provided increased CMF-R (1.3160.02
CMF-R in control vs. 1.4460.04 CMF-R (Ang1) or 1.4160.13
CMF-R (Ang2)). Of note, whereas Ang1 increased PC-R, Ang2
decreased pericyte investment (0.6460.04, Fig. 7C,E). Thus, an
early vessel destabilization regimen, e.g. provided by Ang2 (d0-3),
expanded the vascular growth response of rAAV.Ang1, which
itself was capable of enhancing capillary maturation, but not
capillary growth over time.
Combination of Ang1 and Apelin does not provide
enhanced neovascularization
Finally, we assessed tested the hypothesis that combination of
two vessel maturation agents would not provide enhanced
therapeutic vasularization. APLN, which itself provided increased
perfusion of ischemic mouse hindlimbs (0.8960.06 LDI ratio early
and 1.0460.02 LDI ratio late, Fig. 8A,B), was unable to do so
when combined with Ang1, at the early (0.8260.07 LDI ratio) or
the late timepoint (0.9160.04 LDI ratio, Fig. 8A,B). Moreover,
Ang1 co-expression prohibited capillary growth provided
(1.4260.04 CMF-R) by APLN, but did not affect the pericyte
recruitment induced by APLN alone (0.8460.02 PC-R, Fig. 8C–
E). These data indicate the possibility to prevent therapeutic
neovascularization by capillary sealing with pericyte sheaths,
which in fact decapacitated the otherwise effective growth factor
APLN in combination with the second maturation factor, Ang1.
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Figure 3. rAAV.VEGF-A did not provide enhanced neovascularization at d14. (A, B) Laser Doppler images and quantification of LDI of low
and high VEGF-A groups displayed no difference to controls, similar to the combination of high VEGF-A with Ang2. (C) Fluorescence microscopy
images of gastrocnemius muscle for capillaries (PECAM-1, red), pericytes (NG2, green) and nuclei (DAPI, blue) for the different groups. (D)
Quantification of CMF-R displayed increased capillary growth for high VEGF-A with or without Ang2, whereas (E) PC-R revealed a diminished vessel
maturation only for high VEGF-A combined with Ang2. (MEAN 6 SEM, n = 7,* p,0.05, ** p,0.01).
doi:10.1371/journal.pone.0061831.g003
Role of Vessel Maturation in Neovascularization
PLOS ONE | www.plosone.org 7 April 2013 | Volume 8 | Issue 4 | e61831
Figure 4. Apelin did not provide early neovascularization with Ang2. (A, B) LDI of blood reperfusion induced by APLN is enhanced without
continuous Ang2 overexpression (rAAV.Ang2), where as the combination of APLN and Ang2 displayed no significant alteration. APLN combined with
early Ang2 overexpression (rAAV.Apln+Ang2(d0-3)) induced a trend towards higher perfusion (p = 0.08). (C–E) PECAM-1 positive capillaries were
slightly increased by rAAV.APLN, whereas the combination with continuous rAAV.Ang2 or rAAV.Ang2(d0-3) clearly enhaced capillary formation
compared to APLN alone. Capillary maturation, indicated by pericyte coverage (E) was enhanced by rAAV.APLN with or without rAAV.Ang2(d0-3),
whereas continous Ang2 reduced PC-R. (MEAN 6 SEM, n = 7,* p,0.05, ** p,0.01).
doi:10.1371/journal.pone.0061831.g004
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Discussion
In this study, we elucidated the vital importance of the balance
between capillary proliferation and stabilization in adult postis-
chemic neovascularization. By virtue of continuously or tempo-
rarily active rAAV vectors, we assessed the role of early or
continuous pericyte detachment via Angiopoietin-2. First, we
found that VEGF-A failed to improve perfusion in a mouse
Figure 5. APLN provided late neovascularization, with or without continuous Ang2. (A,B) At d14, LDI indicated an increased perfusion by
APLN with or without continuous Ang2 compared to control. Of note, the effect of APLN was prohibited by Ang2(d0-3). (C,D) At d14, rAAV.APLN
improved capillary growth (CMF-R), when used alone or in combination with continuous Ang2 overexpression and temporary Ang2 (d0-3). (C,E)
Pericyte recruitment was provided by APLN, but not if combined with continuous Ang2 overexpression. (MEAN 6 SEM, n= 7,* p,0.05, ** p,0.01).
doi:10.1371/journal.pone.0061831.g005
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hindlimb ischemia model, a finding further impaired by Ang2 a
second vessel destabilization factor (Fig. 1, 2). Second, we found
that APLN, itself a weaker capillary proliferating agent than high-
VEGF-A, improved perfusion, associated with a high pericyte
coverage (Fig. 1, 3). Addition of Ang2 to APLN, which enhanced
capillary density in the ischemic hindlimb, delayed improvement
Figure 6. Ang1 combined with early Ang2 (d0-3) induces enhanced neovascularization at d7. (A, B) LDI analysis revealed no alteration of
perfusion at d7 by either Ang1 or Ang2 (continuous overexpression), but a significant increase in the Ang1+Ang2(d0-3) group. (C–D) Analysis of
capillaries revealed an elevated CMF-R only in the Ang1 and Ang2(d0-3) group, whereas the capillarization was unaltered if Ang 1 and Ang2 were
overxpressed alone. (C,E) Ang1 alone as well as Ang1+Ang2(d0-3) was capable of enhancing pericytes coverage compared to control, Ang2 alone
had no effect on the pericyte/capillary ratio (PC-R). (MEAN 6 SEM, n = 7,* p,0.05, ** p,0.01).
doi:10.1371/journal.pone.0061831.g006
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of perfusion to the late time point (d14, Fig. 4,5). Combining
APLN and early Ang2 (d0-3) did not improve perfusion in the
same manner. (Fig. 4, 5)
Third, we observed that modulation of the Tie2 receptor by
early Ang2 overexpression in addition to continuous Ang1
expression significantly increased hindlimb perfusion, associated
with an increased capillary growth and maturation (Fig. 6, 7).
Neither Ang1 nor Ang2 overexpression alone was able to
accomplish this effect. Finally, the combination two vessel
stabilizing agents (Ang1 and APLN) abolished therapeutic
Figure 7. Ang1 combined with early Ang2 (d0-3) enhanced neovascularization at d14. (A,B) Ang1 improved hindlimb perfusion only, if
combined with Ang2 (d0-3), a condition which also elevated (C,D) capillary/muscle fiber ratio (CMF-R) and (C,E) pericyte/capillary ratio (PC-R) to a
significant higher level. (MEAN 6 SEM, n = 7,* p,0.05, ** p,0.01).
doi:10.1371/journal.pone.0061831.g007
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Figure 8. Apelin did not enhance neovascularization when combined with Ang1. (A, B) rAAV.APLN combined with rAAV. Ang1 was not
capable of elevating hindlimb perfusion at d7 or d14 achieved by APLN alone. (C–E) The combination of APLN with Ang1 failed to increase capillary
growth at d14, but provided a capillary maturation index (PR-R). (MEAN 6 SEM, n = 7,* p,0.05, ** p,0.01).
doi:10.1371/journal.pone.0061831.g008
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neovascularization achieved by APLN alone, but provided a very
high maturation level, i.e. pericyte coverage (Fig. 8).
These results demonstrate that modulation of the delicate
balance of vessel growth and maturation during postischemic
neovascularization is a complex task. We first established that
prevention of vessel maturation by adding Ang2 to VEGF-A-
treatment is potentially harmful, most likely because VEGF-A
itself is a powerful vessel destabilizing agent [5]. Here, further
destabilization by Ang2 impaired early perfusion (d7), and no
improvement above control levels at the later timepoint (d14),
although VEGF-A+Ang2 treatment enhanced sprouting of vessels
at early and late timepoints (Fig. 2, 5). These results fit the earlier
observation in a genetic model of inducible endothelial Ang2
overexpression at a high dose, which suppressed recovery of
neovascularization in the murine hindlimb ischemia model over
21 d [17]. Potentially, lower doses of Ang2 would be more
desirable, since Felcht et al. recently observed a dual mode of
action of Ang2 [24], acting pro-angiogenic on Tie2-low expressing
endothelial cells, as opposed to the destabilizing activity of Ang2
on Tie2-expression endothelial cells [16]. On the other hand, it
has repetitively been demonstrated that VEGF-A would act more
efficiently in postnatal neovascularization, when coupled to a
vessel stabilization agent such as Ang1 [15] or PDGF-B [6].
This strategy, a combination of a growth and maturation factor
with a vessel destabilizing agent, was pursued by using either
APLN or Ang1 in combination with Ang2. The neovasculatory
potential of apelin was recently investigated, and a distinct
antagonism to the VEGF-A induced hyperpermeability was
revealed [23]. Of note, plasmid transfer of VEGF-A helped to
raise the number of vessels induced by apelin, and provided an
additional gain of perfusion compared to apelin alone. Consis-
tently, in our study the limited capability of APLN to form new
vessels, coupled with a high maturation potential (Fig. 4, 5), was
improved by Ang2. However, this combination did not provide a
further improvement of perfusion of the ischemic hindlimb, if used
continuously, most likely due to the pericyte detachment induced
by Ang2 (Fig. 5E). It is puzzling that the combination of APLN
with early Ang2 overexpression did not further increase perfusion
at the later timepoint (Fig. 5). Although the functions conceptu-
alized before (early destabilization by Ang2 followed by enhanced
maturation by APLN) can be demonstrated in vitro (Fig. 1) and in
vivo (Fig. 3, 7), the efficacy of this approach is lacking in a clearcut
and statistical significant manner. Obviously, this combination
becomes dependent on the Ang2 effect, the subtraction of which
by switching off the inducible vector compromises other compo-
nents of the vessel growth process which cannot be compensated
by APLN furtheron.
In order to rule out unforeseen effects of Ang2 on the
maturation principle such as APLN, we speculated that combining
early vessel destabilization via Ang2 with continuous Ang1
overexpression might provide a more balanced vessel growth than
combination of Ang2 with other vasoactive agents. Since neither
Ang1 nor Ang2 alone had an effect on perfusion recovery, we were
surprised to note that the short Ang2-overexpression (d0-3), which
did not increase the perfusion achieved in the APLN series (Fig. 4,
5), was highly efficient in raising the perfusion. Of note, several
studies have reported a boost of the vascular growth response by
late Ang1 addition [25]. Thus, remodeling the physiologic
sequence of early Ang2 induction and subsequent Ang1 increase
found in postischemic myocardial tissue [26] may serve the cause
of early vessel destabilization and subsequent pericyte recruitment.
The continuous Ang1 increase seems instrumental for vascular
integrity and prevention of vessel regression, as observed in
development [27] and in tumor vasculature [28].
The pro-angiogenic effects seen with the combination of a vessel
destabilization (Ang2) and a subsequent vessel maturation (APLN or
Ang1, Fig 5, 7) display a perfusion rate which is above 1, pointing to
a supra-physiological perfusion. An improved perfusion index .1
after hindlimb ischemia in mice was already shown by Abe and
colleagues. They demonstrated a blood flow recovery rate of 1.4–
1.6 (LDI ratio R/L) at 14 days after repeated adrenomedullin
pcDNA injection in a model of hindlimb ischemia. [29] In addition,
values of LDI ratio right to left of 1 can already be achieved in
control mice, depending on their age and genetical background.
[30] [31] Furthermore, the operation technique (ligation vs. excision
of the femoral artery) clearly influences the flow reduction and
recovery capacity in this hindlimb ischemia model in mice. [30] [32]
Taken together, these data confirm that a perfusion index .1 can
be achieved, but might be dependent on the longterm or repeated
overexpression of the right transgene. In addition, the mouse model
of femoral artery ligation has high recovery capacity; therefore
results should be viewed as a first evidence for a therapeutic
treatment. Furthermore it allows some insights into signaling
cascades and pathophysiological correlations. These concepts need
to be reassessed in additional (more stable) animal models before
translated to a clinical situation.
In summary, we showed that the concept of early vessel
destabilization and late maturation is valid in providing enhanced
postischemic hindlimb perfusion. We demonstrated that combin-
ing two destabilizing agents (VEGF-A and Ang2) at times
deteriorates perfusion, whereas the combination of two growth
and maturation factors (Ang1 and APLN) can even prohibit the
efficacy of one (APLN) when applied alone. However, the choice
of vascular agents is delicate: in our model, only the sequence of
early Ang2 overexpression combined with continuous Ang1
overexpression provided enhanced perfusion, even superior to
APLN, due to a induction of mature microvessels. However, this
concept might add to the armamentarium of therapeutic
approaches of chronic ischemic muscle disease.
Supporting Information
Figure S1 Efficacy of rAAV mediated growth factor
transduction. Intramuscular injection of rAAV.VEGF-A (A),
rAAV.Ang2 (B) and rAAV.APLN (C) into the ischemic limb
displayed a significant increase of mRNA levels compared to the
non-injected sham operated leg as well as to controls (displayed as
DDCT normalized to S18, day 7 post ligation). (D) Analysis of
Ang1 levels revealed higher DDCT levels at day 3 post ligation as
well as on day 7, when Doxycycline was applied. (E) rAAV.Ang2
(day0-3) transduction showed enhanced Ang2 levels at day 3 (no
Doxycycline) and a clear reduction of Ang2 at day 7 when the
vector was shut off by Doxycycline. (F) I.m. injection of
rAAV.LacZ revealed a clear blue staining for ß-Galaktosidase in
the treated leg compared to control. (MEAN 6 SEM, n= 3,
** p,0.05).
(TIF)
Figure S2 In vitro expression analysis. Pericytes (C3H/
10T1/2) obtain from ATCC, express pericyte markers as NG2 (A)
and PDGF-R (B) in FACS analysis. To asure that the co-
transfection of two transgenes within one approach does not alter
the expression level, RT-PCR analysis were performed. (C,D)
APLN as well as Ang2 display the same expression level if
transfected alone or in combination for DDCT of APLN or Ang2.
(E;F) Analysis of cells transfected with VEGF alon or in
combination with Ang2 revieled similar expression levels for
DDCT of VEGF or Ang2 in both groups.
(TIF)
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Figure S3 In vitro pericyte recruitment. (A) 16103
Pericytes labeled by DiO (green) are plated after capillary-like
tube formation of bEnd.3 cells (murine endothelial cells) with DiD
labeling (red). 24 h later, co-cultures reveal a low rate of pericytes
attraction by VEGF-A, which was unaffected by Ang2. (B)
Pericyte recruitment to the murine endothelial cells was enhanced
by APLN, an effect attenuated by Ang2. (C) However, the tube
maturation of the bEnd.3 cells provided by Ang1 was abolished in
the presence of Ang2. (MEAN 6 SEM, n= 5, ** p,0.01).
(TIF)
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